Prosus (OTCMKTS:PROSY) & PetMed Express (NASDAQ:PETS) Head to Head Review

PetMed Express (NASDAQ:PETS) and Prosus (OTCMKTS:PROSY) are both retail/wholesale companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Risk and Volatility

PetMed Express has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Prosus has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Profitability

This table compares PetMed Express and Prosus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PetMed Express	-2.76%	-6.76%	-4.24%
Prosus	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings for PetMed Express and Prosus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetMed Express	2	1	0	0	1.33
Prosus	0	0	3	1	3.25

PetMed Express presently has a consensus target price of $3.20, indicating a potential upside of 8.84%. Given PetMed Express’ higher possible upside, equities research analysts plainly believe PetMed Express is more favorable than Prosus.

Earnings & Valuation

This table compares PetMed Express and Prosus”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetMed Express	$226.97 million	0.28	-$6.27 million	($0.30)	-9.80
Prosus	$6.17 billion	54.07	$12.37 billion	N/A	N/A

Prosus has higher revenue and earnings than PetMed Express.

Insider and Institutional Ownership

73.3% of PetMed Express shares are owned by institutional investors. Comparatively, 0.0% of Prosus shares are owned by institutional investors. 1.1% of PetMed Express shares are owned by insiders. Comparatively, 0.5% of Prosus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Prosus beats PetMed Express on 9 of the 13 factors compared between the two stocks.

About PetMed Express

PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.

About Prosus

Prosus N.V. engages in the e-commerce and internet businesses in Asia, Europe, Latin America, North America, and internationally. It operates internet platforms, such as classifieds, payments and fintech, food delivery, education technology, etail, ventures, social, and other internet platforms. The company was formerly known as Myriad International Holdings N.V. and changed its name to Prosus N.V. in August 2019. Prosus N.V. was incorporated in 1994 and is headquartered in Amsterdam, the Netherlands. Prosus N.V. operates as a subsidiary of Naspers Limited.